Selumetinib, a selective MEK1/2 inhibitor, achieved objective responses in 15% of patients with recurrent low-grade serous ovarian cancer (LGSOC). The data are relevant as this uncommon tumor type is associated with general chemoresistance, frequent aberration in the MAPK pathway, and prolonged overall survival compared with its more common high-grade variant. Phase 3 trials are planned.
In this randomized, controlled trial, tranexamic acid and mefanamic acid were no better than placebo in reducing the number of bleeding or spotting days in the first 3 months after LNG-IUS placement.
Childhood chronic inflammatory demyelinating polyradiuculoneuropathy follows a similar course as the adult counterpart and responds well to treatment with intravenous immunoglobulin.
In this issue: Aspirin use and AMD risk; using NSAIDs and antihypertensive agents; and FDA actions.
